A Phase 4 interventional study of Maximal Hyperemia with Adenosine Followed by Nicorandil and Maximal Hyperemia with Nicorandil Followed by Adenosine in Coronary Artery Disease and Myocardial Ischemia, sponsored by Seoul National University Hospital. Status unknown at 1 site in Korea, Republic of. Per ClinicalTrials.gov, last updated 2011-04-08.
Sponsored by Seoul National University Hospital · Phase 4, Interventional, and Diagnostic
The purpose of this study is to evaluate the efficacy of nicorandil in the achievement of maximal coronary hyperemia compared with adenosine.
5,596 studies on the registry are indexed under Coronary Artery Disease; 955 are open to participants now.
This study's planned enrollment of 200 is above the median of 123 across 3,435 interventional studies indexed under Coronary Artery Disease.
Browse Coronary Artery Disease studies →Seoul National University Hospital is the lead sponsor of 1,860 studies on the registry; 275 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Other: Maximal Hyperemia with Adenosine Followed by Nicorandil
Other: Maximal Hyperemia with Nicorandil Followed by Adenosine
Firstly FFR was measured with intravenous adenosine infusion (140 μg•min-1•kg-1) via femoral vein or antecubital vein. Secondly with intracoronary adenosine bolus injection (80μg, 40μg to LCA and RCA, respectively). Lastly with intracoronary nicorandil bolus injection (1mg followed by 2mg).
Firstly FFR was measured with intracoronary nicorandil bolus injection (1mg followed by 2mg). Secondly with intravenous adenosine infusion (140 μg•min-1•kg-1) via femoral vein or antecubital vein. Lastly with intracoronary adenosine bolus injection (80μg, 40μg to LCA and RCA, respectively).
Fractional Flow Reserve at Maximal Hyperemia
Time frame: 1 day
Time to Maximal Hyperemia
Time frame: 1 day
Changes in Heart Rate
Time frame: 1 day
This study is status unknown, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seoul National University Hospital